GlassScriptPhysician profile
Michelle Sirman-Wells
NPI 1427450469
$3,146.12
in general payments reported to CMS, 2019-2025
27 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $248 · 2023: $1,187 · 2024: $523 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $439.87 | 2023-2025 | Epclusa, Biktarvy |
| Abbvie INC. | $289.93 | 2022-2025 | |
| Novo Nordisk INC | $250.19 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.54 | 2023-2025 | |
| Madrigal Pharmaceuticals | $146.48 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $141.24 | 2025 | Amvuttra |
| Cvrx, INC. | $133.31 | 2024 | Barostim Neo System |
| Neurocrine Biosciences, INC. | $125.00 | 2023 | Ongentys |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Arexvy |
| Sanofi-Aventis U.S. LLC | $124.99 | 2025 | |
| Idorsia Pharmaceuticals US INC | $117.77 | 2023 | Quviviq |
| Insmed, INC. | $114.64 | 2023 | Arikayce |
| Atricure, INC. | $106.55 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $106.13 | 2022 | |
| Acadia Pharmaceuticals INC | $104.19 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $102.75 | 2023 | Intellis Adaptivestim |
| Biogen, INC. | $100.83 | 2024 | |
| Abbott Laboratories | $92.54 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.11 | 2025 | |
| Csl Behring | $45.27 | 2023 | Kcentra |
| Emd Serono, INC. | $43.27 | 2023 | Mavenclad |
| Merz Pharmaceuticals, LLC | $32.41 | 2022-2024 | Ampyra, Xeomin, Inbrija |
| Teva Pharmaceuticals USA, INC. | $23.74 | 2023 | Austedo Xr |
| Ucb, INC. | $20.62 | 2023 | Briviact |
| Genentech USA, INC. | $18.95 | 2024 | Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $18.57 | 2023 | Soliris |
| Curonix LLC | $13.24 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Sirman-Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.